Amit Bar-Or

Director, Center for Neuroinflammation and Neurotherapeutics · University of Pennsylvania Health System

Credentials: · · ·

History

Center for Neuroinflammation and Neurotherapeutics · University of Pennsylvania Health System
Present
Multiple Sclerosis Division · University of Pennsylvania Health System
Present
Department of Neurology Division · University of Pennsylvania Health System
Present

AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $1.3M · University of Pennsylvania
2026–2033
Deep Phenotyping of DR15-Restricted CD4+ T Cells Specific for Epstein-Barr Virus Epitopes in the Spinal Fluid and Blood of People with Multiple Sclerosis
National Institute of Allergy and Infectious Diseases · R21
PI · $247.5K · Massachusetts General Hospital
2026–2028
University of Pennsylvania Clinical Autoimmunity Center of Excellence
National Institute of Allergy and Infectious Diseases · UM1
PI · $550.6K · University of Pennsylvania
2019–2024
Molecular Profiling of Exosomes from Multiple Sclerosis B Cells
National Institute of Neurological Disorders and Stroke · R21
PI · $447K · Wayne State University
2020–2023

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation
Principal investigator · Enrolling by invitation
University of Pennsylvania
2022–2027
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
Principal investigator · Completed
McGill University
2012–2018
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Study chair · Active not recruiting · Phase 4
National Institute of Allergy and Infectious Diseases (NIAID)
2023–2032
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Study chair · Terminated · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2021–2024